Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 9/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14640439 | 0.88 | KAT2B (0.46) | KAT2BMEN1MAPTKMT2AHTT | |
| SCHEMBL5593840 | 0.80 | KAT2B (0.49) | KAT2BMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL80967 | 0.78 | KAT2B (0.58) | KAT2BMAPTHTTHPGDALDH1A1 | |
| SCHEMBL5917410 | 0.78 | LMNA (0.50) | KAT2BMEN1MAPTKMT2AHPGD | |
| SCHEMBL5917409 | 0.78 | LMNA (0.50) | KAT2BMEN1MAPTKMT2AHPGD | |
| SCHEMBL14640402 | 0.78 | LMNA (0.50) | KAT2BMEN1MAPTKMT2AHPGD | |
| SCHEMBL14640438 | 0.77 | KAT2B (0.49) | KAT2BMEN1MAPTKMT2AHTT | |
| Hydrochloric Acid SCHEMBL9517520 | 0.77 | KAT2B (0.56) | KAT2BMAPTHTTHPGDALDH1A1 | |
| SCHEMBL5593775 | 0.77 | KAT2B (0.49) | KAT2BMAPTHTTHPGDALDH1A1 | |
| SCHEMBL14640434 | 0.74 | KAT2B (0.46) | KAT2BMAOBMAOAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001932-A2 | SUBSTITUTED ISOTHIAZOLONES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007001932-A2 | SUBSTITUTED ISOTHIAZOLONES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293374-A1 | Substituted isothiazolones | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293374-A1 | Substituted isothiazolones | LTB4R2, PTGES2, CYSLTR2 | KAT2B 1199/4885MAOB 1810/4885MAOA 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.